Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 24:12:727245.
doi: 10.3389/fphar.2021.727245. eCollection 2021.

Predicting Blood Concentration of Tacrolimus in Patients With Autoimmune Diseases Using Machine Learning Techniques Based on Real-World Evidence

Affiliations

Predicting Blood Concentration of Tacrolimus in Patients With Autoimmune Diseases Using Machine Learning Techniques Based on Real-World Evidence

Ping Zheng et al. Front Pharmacol. .

Abstract

Tacrolimus is a widely used immunosuppressive drug in patients with autoimmune diseases. It has a narrow therapeutic window, thus requiring therapeutic drug monitoring (TDM) to guide the clinical regimen. This study included 193 cases of tacrolimus TDM data in patients with autoimmune diseases at Southern Medical University Nanfang Hospital from June 7, 2018, to December 31, 2020. The study identified nine important variables for tacrolimus concentration using sequential forward selection, including height, tacrolimus daily dose, other immunosuppressants, low-density lipoprotein cholesterol, mean corpuscular volume, mean corpuscular hemoglobin, white blood cell count, direct bilirubin, and hematocrit. The prediction abilities of 14 models based on regression analysis or machine learning algorithms were compared. Ultimately, a prediction model of tacrolimus concentration was established through eXtreme Gradient Boosting (XGBoost) algorithm with the best predictive ability (R 2 = 0.54, mean absolute error = 0.25, and root mean square error = 0.33). Then, SHapley Additive exPlanations was used to visually interpret the variable's impacts on tacrolimus concentration. In conclusion, the XGBoost model for predicting blood concentration of tacrolimus on the basis of real-world evidence has good predictive performance, providing guidance for the adjustment of regimen in clinical practice.

Keywords: autoimmune disease; blood concentration prediction; machine learning; tacrolimus; therapeutic drug monitoring.

PubMed Disclaimer

Conflict of interest statement

Author ZY, PY, QQ, ZW, and FG were employed by Beijing Medicinovo Technology Co. Ltd. Author XH is employed by Dalian Medicinovo Technology Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Workflow of patients selection.
FIGURE 2
FIGURE 2
R 2 (A), MAE, and RMSE (B) corresponding to the number of ranked variables.
FIGURE 3
FIGURE 3
Scatter plot of actual and predicted tacrolimus TDM value.
FIGURE 4
FIGURE 4
SHAP values of the important risk factors. The dot color is redder when the feature value gets higher and bluer when the feature value gets lower. When the SHAP value gets higher, the impact of the variable on model output is larger.

Comment in

Similar articles

Cited by

References

    1. Aha D. W., Kibler D., Albert M. K. (1991). Instance-based Learning Algorithms. Mach. Learn. 6, 37–66. 10.1007/bf00153759 - DOI
    1. Andrews L. M., Li Y., De Winter B. C. M., Shi Y. Y., Baan C. C., Van Gelder T., et al. (2017). Pharmacokinetic Considerations Related to Therapeutic Drug Monitoring of Tacrolimus in Kidney Transplant Patients. Expert Opin. Drug Metab. Toxicol. 13 (12), 1225–1236. 10.1080/17425255.2017.1395413 - DOI - PubMed
    1. Bellarosa C., Bortolussi G., Tiribelli C. (2009). The Role of ABC Transporters in Protecting Cells from Bilirubin Toxicity. Curr. Pharm. Des. 15 (25), 2884–2892. 10.2174/138161209789058246 - DOI - PubMed
    1. Breiman L. (2001). Random Forests. Mach. Learn. 45, 5–32. 10.1023/a:1010933404324 - DOI
    1. Brunet M., van Gelder T., Åsberg A., Haufroid V., Hesselink D. A., Langman L., et al. (2019). Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther. Drug Monit. 41 (3), 261–307. 10.1097/FTD.0000000000000640 - DOI - PubMed

LinkOut - more resources